丹参多酚酸盐联合阿托伐他汀对老年急性冠状动脉综合征患者经皮冠状动脉介入治疗术后血管内皮功能及炎性因子的影响  

Effect of salvianolate combined with atorvastatin on endothelial function and inflammatory factors in patients with acute coronary syndrome after percutaneous coronary intervention

作　　者：唐群中[1] 张学频[1] 陈学智[1] 唐强[1] 

机构地区：[1]北京大学首钢医院心血管内科,北京100041

出　　处：《中国介入心脏病学杂志》2015年第5期282-285,共4页Chinese Journal of Interventional Cardiology

摘　　要：目的探讨丹参多酚酸盐联合阿托伐他汀对急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后血管内皮功能及炎性因子的影响,为临床治疗ACS提供依据。方法纳入2010年1月至2012年1月北京大学首钢医院收治的100例ACS患者作为研究对象,均接受PCI治疗。随机分为对照组50例和观察组50例,对照组给予阿托伐他汀治疗,观察组给予丹参多酚酸盐联合阿托伐他汀治疗。比较两组患者治疗前后血管功能指标、炎性因子水平及并发症发生情况。结果治疗后两组患者内皮素-1(ET-1)、一氧化氮(NO)、血管性假血友病因子(v WF)和血流依赖性舒张功能(FMD)等血管内皮功能指标较治疗前均改善,但观察组血管内皮功能指标较对照组改善程度更为显著,差异有统计学意义(P<0.05)。治疗后两组患者肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和C反应蛋白(CRP)等炎性因子水平较治疗前均降低,但观察组炎性因子水平比对照组改善程度更为显著,差异有统计学意义(P<0.05)。观察组随访期间主要不良心脏事件发生率仅为2.0%,显著低于对照组(12.0%),差异有统计学意义(P<0.05)。结论丹参多酚酸盐联合阿托伐他汀治疗可显著改善ACS患者PCI术后血管内皮功能,并降低其炎性因子水平,其机制值得进一步研究。Objective To investigate the clinical effect of salvianolate combined with atorvastatin on endothelial function and inflammatory factors in patients with acute coronary syndrome （ACS） after percutaneous coronary intervention （PCI） . Methods From January 2010 to January 2012, we collected 100 ACS cases treated with PCI in our hospital and divided them into 2 groups randomly, 50 cases in control group and 50 cases in salviandate treatment group. Besides conventional treatments, the control group was treated with atorvastatin and the observation group was given salvianolate combined with atorvastatin. Parameters of endothelial function including ET-1, NO, vWF and FMD, inflammatory factors including TNF- α, IL-6 and CRP, and clinical complications were observed and compared between the 2 groups before and after treatment. Results Compared with the levels before treatment, the levels of ET-1, NO, vWF and FMD were all improved after treatment in both groups （ all P 〈 0. 05） . Compared with the post treatment levels in the control group, ET-1 [ （64.3 ±4.9） ng/Lvs. （86.3±5.6） ng/L], NO [ （69.5 ±7.9） μmol/L vs. （62.3±8.4） μmol/L], vWF [ （112.6±11.9）% vs. （146.7±13.4）%] and FMD [ （6.3 ±0. 9）% vs. （4. 1 ＋0. 8）% ] all showed better improvement in the salvianolate group （all P 〈 0. 05 ） . Inflammatory factors including TNF-α, IL-6 and CRP were all decreased in both groups after treatment as compared to pre-treatment levels （ all P 〈 0. 05 ） . More significant decrease after treatment was found in the salvianolate treatment group in TNF-α [ （26. 36 ±13.03） pg/ml vs. （53.44 ± 11.32） pg/ml] , IL-6 [ （16.31 ±8.99） pg/mlvs. （30.22±11.11） pg/ml] andCRP [ （7.53 ±2.37） mg/mlvs. （11.33± 2.46 ） mg/ml ] compared with the control group （ all P 〈 0. 05 ） . Adverse events rate was 2.0% in the salvianolate treatment group and 12. 0% in the control group （P 〈 0.05 ） . Conclusions Combined treatment of salvianolate with atorvastat

关 键 词：经皮冠状动脉介入治疗 急性冠状动脉综合征 丹参多酚酸盐 阿托伐他汀 

分 类 号：R541.4[医药卫生—心血管疾病]